PRECIGEN, INC. Precigen's virtual R&D day event will showcase complete clinical trial safety and efficacy data from the Phase 1 dose escalation and expansion cohorts and will be led by Clint T. Allen, MD, Senior Investigator, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute (NCI) and lead associate investigator for the PRGN-2012 clinical trial and Precigen's President and CEO, Helen Sabzevari, PhD. Both presenters will participate in a Q&A following the presentation.
Supporting Materials
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Precigen Inc. published this content on 24 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 January 2023 16:51:02 UTC.
